Research

Data mining of the transcriptome of *Plasmodium falciparum*: the pentose phosphate pathway and ancillary processes

Zbynek Bozdech¹ and Hagai Ginsburg*²

Address: ¹School of Biological Sciences, Nanyang Technological University, 637551 Singapore and ²Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel

Email: Zbynek Bozdech - ZBozdech@ntu.edu.sg; Hagai Ginsburg* - hagai@vms.huji.ac.il

* Corresponding author

Abstract

The general paradigm that emerges from the analysis of the transcriptome of the malaria parasite *Plasmodium falciparum* is that the expression clusters of genes that code for enzymes engaged in the same cellular function is coordinated. Here the consistency of this perception is examined by analysing specific pathways that metabolically-linked. The pentose phosphate pathway (PPP) is a fundamental element of cell biochemistry since it is the major pathway for the recycling of NADP⁺ to NADPH and for the production of ribose-5-phosphate that is needed for the synthesis of nucleotides. The function of PPP depends on the synthesis of NADP⁺ and thiamine pyrophosphate, a co-enzyme of the PPP enzyme transketolase. In this essay, the transcription of gene coding for enzymes involved in the PPP, thiamine and NAD(P)⁺ synthases are analysed. The genes coding for two essential enzymes in these pathways, transaldolase and NAD⁺ kinase could not be found in the genome of *P. falciparum*. It is found that the transcription of the genes of each pathway is not always coordinated and there is usually a gene whose transcription sets the latest time for the full deployment of the pathway’s activity. The activity of PPP seems to involve only the oxidative arm of PPP that is geared for maximal NADP⁺ reduction and ribose-5-phosphate production during the early stages of parasite development. The synthesis of thiamine diphosphate is predicted to occur much later than the expression of transketolase. Later in the parasite cycle, the non-oxidative arm of PPP that can use fructose-6-phosphate and glyceraldehyde-3-phosphate supplied by glycolysis, becomes fully deployed allowing to maximize the production of ribose-5-phosphate. These discrepancies require direct biochemical investigations to test the activities of the various enzymes in the developing parasite. Notably, several transcripts of PPP enzyme-coding genes display biphasic pattern of transcription unlike most transcripts that peak only once during the parasite cycle. The physiological meaning of this pattern requires further investigation.

Introduction

The analysis of the transcriptome of *Plasmodium falciparum* has revealed that during the intraerythrocytic development of the parasite, genes coding for enzymes and proteins that are involved in complex cellular functions such as transcription, replication or energy metabolism, each involving many gene products, are transcribed in a coordinated fashion, supporting the notion that all components must be present at the right time to allow for optimal function [1-3]. While this may be true in general, it has already been found that scrutinizing the details of specific metabolic functions reveal some significant
departures from this paradigm [4]. Such scrutiny has also provided some intriguing peculiarities that through detailed biochemical studies may reveal some parasite-specific functions that may enlighten our understanding of parasitism or even provide for novel targets for chemotherapeutic intervention. The present analysis explores of the transcriptome to fathom additional metabolic pathways.

During the erythrocytic stage the malaria parasite is engaged in intensive synthesis of nucleotides and is subjected to endogenously produced oxidative radicals that must be detoxified. Like other cells, in order to perform its anabolism, the parasite needs not only energy (ATP): it also needs reducing power, under the form of NADPH. Enzymes that function primarily in the reductive direction utilize NADP+/NADPH pair as co-factors as opposed to oxidative enzymes that utilize the NAD+/NADH cofactor pair. The conversion of ribonucleotides to deoxyribonucleotides (through the action of ribonucleotide reductase) requires NADPH as the electron source. Thus, any cell that proliferates rapidly requires large quantities of NADPH. NADPH can be produced during glucose-6-phosphate oxidation through the pentose-phosphate pathway (PPP; Figure 1). This pathway also produces ribose-5-phosphate (R5P), the sugar component of nucleic acids.

The reactions of the PPP operate exclusively in the cytoplasm. PPP has both an oxidative and a non-oxidative arm. The oxidation steps, utilizing glucose-6-phosphate (G6P) as the substrate, occur at the beginning of the pathway and are the reactions that generate NADPH. Thus, the first carbon of glucose-6-phosphate is first oxidized to a lactone (catalyzed by glucose-6-phosphate dehydrogenase) concomitantly releasing two electrons that reduce one molecule of NADP+ to NADPH. The ensuing decarboxylation of 6-phospho-D-gluconate (catalyzed by 6-phosphogluconate dehydrogenase) releases two additional electrons, which reduce a second molecule of NADP+. A five-carbon sugar, D-ribulose-5-phosphate, is produced in the reaction. By isomerization, D-ribulose-5-phosphate is transformed into D-ribose-5-phosphate (R5P). To be used in nucleic acid synthesis, R5P is transformed into 5-Phospho-8-D-ribose 1-pyrophosphoric acid (PRPP) by ribose-phosphate diphosphokinase (EC: 2.7.6.1).

The non-oxidative reactions of the PPP are primarily designed to generate R5P. Equally important reactions of the PPP are to convert dietary 5 carbon sugars or D-ribose-1-phosphate generated in the salvage of purines (that can be slowly converted to R5P by phosphoglucomutase; EC: 5.4.2.2) into both 6 (fructose-6-phosphate) and 3 (glycer-aldehyde-3-phosphate) carbon sugars which can then be utilized by the pathways of glycolysis. In the first reaction, R5P will accept two carbon atoms from xylulose-5-phosphate (obtained by epimerization of ribulose-5-P), yielding sedoheptulose-7-phosphate and glyceraldehyde-3-phosphate (catalyzed by transketolase). Sedoheptulose-7-phosphate transfers three carbons to glyceraldehyde-3-phosphate (catalyzed by transaldolase), yielding fructose-6-phosphate (F6P) and erythrose-4-phosphate. Erythrose-4-phosphate then accepts two carbon atoms from a second molecule of xylulose-5-phosphate (catalyzed again by transketolase), yielding a second molecule of F6P and a glyceraldehyde-3-P (GAP) molecule. F6P and a GAP can then enter glycolysis and eventually produce ATP. The intermediate erythrose-4-phosphate is a substrate for the shikimate pathway.

The non-oxidative part of PPP can also work in the reverse direction utilizing fructose-6-phosphate glyceraldehyde-3-phosphate generated by glycolysis to produce ribose-5-phosphate. In essence, the PPP can operate in different modes (Figure 2). When both R5P and NADPH are needed (Figure 2 mode 1) only the oxidative path will operate: all the ribulose 5-phosphate is isomerized to R5P and the pathway is completed. When more ribose-5-phosphate than NADPH is needed (Figure 2 mode 2), R5P is synthesized by a reversion of the non-oxidative path from F6P and GAP generated by glycolysis. When the cell needs both NADPH and ATP but not R5P (Figure 2 mode 3); ribulose-5-phosphate is converted to F6P and GAP for glycolysis to make ATP and NADH.

The genes that code for enzymes participating in ancillary processes that produce NADP+ and thiamine pyrophosphate, that serves as a co-factor for transketolase activity, should be expressed in coordination with the enzymes of the PPP. The details of the mentioned pathways can be also grasped at (http://sites.huji.ac.il/malaria/maps/nicotinametpath.html; http://sites.huji.ac.il/malaria/maps/thiaminemetpath.html, respectively) and the time-dependent transcription of the genes coding for the different enzymes will be discussed below.

PPP activity in P. falciparum-infected erythrocytes has been measured [5-7]. The reverse activity of the non-oxidative arm of PPP has also been demonstrated by measuring the incorporation of radiolabel from [1-14C]glucose into nucleotides [6,8]. The former investigators have shown that 4/5 of the glucose incorporated into parasite nucleic acids comes from the condensation of F6P and GAP in the reverse action of this arm. Atamma et al, reported that infected cells have large increase of PPP activity where 82% is contributed by the parasite while the host cell's PPP activity is activated some 24-fold as a result of the oxidative stress that the parasite generates and impinges on the host cell [9].
The gene coding for G6PD has been cloned [10] and the biochemical properties of the isolated enzyme have been characterized [11,12]. Molecular investigations have revealed that G6PD is coded by a hybrid gene that contains also the sequence of 6-phosphogluconolactonase (the second enzyme of PPP) [13,14]. Activity of 6-phosphogluconate dehydrogenase in \textit{Plasmodium}-infected erythrocytes has been detected indirectly and alluded to a parasite enzyme, but not characterized [15-17]. Ribose-phosphate diphosphokinase of \textit{P. falciparum} activity has been characterized and levels of its product 5'-phosphoribosyl-pyrophosphate (PRPP) were measured in \textit{P. falciparum}-infected erythrocytes [8,18]. The levels of PRPP were found to be increased 56-fold in infected cells at the trophozoite stage compared to uninfected erythrocytes.

The parasite contains substantial levels of the pyridine nucleotides NAD$^+$ and NADPH and their reduced forms [19] and jointly with the presence of genes coding for the enzymes necessary for their synthesis in the genome of \textit{P. falciparum}.
falciparum (but see below the discussion concerning the absence of NAD^+ kinase-coding gene), indicate the ability of the parasite to produce these co-factors. NADP^+ and NADPH are used by several biochemical reactions in the parasite (Table 1), but the major role of NADP^+ is probably in the antioxidant defense of the parasite [20,21] (see http://sites.huji.ac.il/malaria/maps/redoxmetpath.html for details). Interestingly enough, the biochemical (such as the intermediate products, enzyme activities for each step, timing of production?) details of NAD(P)^+ synthesis in the parasite such as the intermediate products, enzyme activities for each step, timing of production, were not investigated.

In this in silico analysis, the stage-dependent transcription of genes that code for enzymes that are involved in the PPP activity of the parasite will be analyzed in a functional context.
Materials and methods

The expression data used in this study was obtained from the transcriptome database http://malaria.ucsf.edu/ of the P. falciparum intraerythrocytic developmental cycle as described [2]. This database contains the relative mRNA abundance for every hour of the intraerythrocytic cycle of parasite development based on the 70-mer oligonucleotide microarray [22]. The expression profile of each transcript is represented by an array of ratios between the mRNA level in the time point sample versus a fixed mRNA level in the control RNA pool. Loess smoothed expression profiles used in this study were calculated as described (see [2]). The peak hour induction was calculated from these profiles. This represents more accurate estimate of

Table 1: NADP utilizing enzymes Enzymes are arranged by their sequential functional order. They are given by their name, their EC numbers, the gene identification (PfID) in the Plasmodium genome database (PlasmoDB), the time (in hours post invasion (HPI)) in the parasite’s developmental cycle when they are maximally transcribed obtained from the IDC database and the metabolic function of the enzyme.

| Enzyme                                      | EC number   | PfID      | Peak (HPI) | Metabolic function          |
|---------------------------------------------|-------------|-----------|------------|-----------------------------|
| 3-oxoacyl-[acyl-carrier-protein] reductase   | 1.1.1.100   | PF11125c  | 28         | Fatty acid synthesis        |
| 1-deoxy-D-xylulose-5-phosphate reductoisomerase | 1.1.1.267   | PF14 0641 | 30         | Isoprenoid metabolism       |
| Isocitrate dehydrogenase (NADP+)             | 1.1.1.42    | PF13 0242 | 28         | TCA cycle                   |
| Phosphoglucuronate dehydrogenase             | 1.1.1.44    | PF14 0520 | 26         | PPP                         |
| Glucose-6-phosphate 1-dehydrogenase;         | 1.1.1.49    | PF14 0511 | 48         | PPP                         |
| Pyruvate dehydrogenase (acetyltransferring); | 1.2.4.1     | PF11 0256 PF14 0441 | 28 28 | Pyruvate metabolism         |
| Glutamate dehydrogenase (NADP)               | 1.4.1.4     | PF14 0164 PF14 0286 | 1 30 | Glutamate metabolism        |
| Pyrroline-5-carboxylate reductase             | 1.5.1.2     | MAL13P1.284 | 18       | Proline metabolism          |
| Dihydrolipoamide reductase                   | 1.5.1.3     | PFD0830w  | 26         | Folate synthesis             |
| NAD(P)+ transhydrogenase (B-specific);       | 1.6.1.1     | PF14 0508 | 32         | ?                           |
| NADPH hemoprotein reductase                  | 1.6.2.4     | PF11 140w | 13         | Flavoprotein reduction       |
| Dihydrolipoamide dehydrogenase               | 1.8.1.4     | PF08 0066 PF13 1550 | 28 11 | Pyruvate metabolism         |
| Dihydrolipoamide S-acetyltransferase;        | 2.3.1.12    | PF10 0407 | 28         | Pyruvate metabolism         |

Table 2: Enzymes of the pentose phosphate pathway and pyridine nucleotide metabolism. Enzymes are grouped into pathways. They are given by their name, their EC numbers, the gene identification (PfID) in the Plasmodium genome database (PlasmoDB), the time (in hours post invasion (HPI)) in the parasite’s developmental cycle when they are maximally transcribed obtained from the IDC database and the metabolic function of the enzyme.

| Pathway                  | Enzyme                              | EC number   | PfID      | Peak (HPI) |
|--------------------------|-------------------------------------|-------------|-----------|------------|
| Pentose phosphate pathway| Glucose-6-phosphate dehydrogenase   | 1.1.1.49    | PF14 0511 | 48         |
|                         | 6-phosphogluconolactonase           | 3.1.1.31    | PF14 0511 | 48         |
|                         | 6-phosphogluconate dehydrogenase    | 1.1.1.44    | PF14 0520 | 26         |
|                         | Ribulose 5-phosphate 3-epimerase    | 5.1.3.1     | PFL0960w  | 29         |
|                         | Ribose 5-phosphate isomerase        | 5.3.1.6     | PFE0730c  | 21         |
|                         | Transketolase                       | 2.2.1.1     | MAL6P1.110| 17         |
|                         | Ribose phosphate diphosphokinase    | 2.7.6.1     | PF13 0143 PF13 0157 | 21 21 |
|                         | Deoxyribose phosphate aldolase      | 4.1.2.4     | PF10 0210 | 21         |
|                         | Phosphoglucomutase                  | 5.4.2.2     | PF10 0122 | 21         |
| Pyridine nucleotide metabolism | Nicotinamidase                     | 3.5.1.19    | chr3.glm 243 | 18, 38 |
|                         | Nicotinasephosphoribosyl transferase | 2.4.2.11    | chr6.glm 337 | 25         |
|                         | Nicotinate-nucleotide adenylyl transferase | 2.7.7.18 | chr13.glm 329 | 20, 40 |
|                         | NAD+ synthetase                     | 6.3.5.1     | PF1310w   | 28         |
|                         | Pyridine nucleotide transhydrogenase| 1.6.1.1     | PF14 0508 | 32         |
| Thiamine metabolism     | Hydroxyethylthiazole kinase         | 2.7.1.50    | PFL1920c  | 22         |
|                         | Hydroxymethylpyrimidine kinase      | 2.7.1.49 2.7.4.7 | PF1030c | 33         |
|                         | Phosphohomopyrimidine kinase        |             |           |            |
|                         | Thiamine-phosphate diphosphorylase  | 2.5.1.3     | MAL6P1.285 | 1         |
|                         | Thiamine diphosphokinase            | 2.7.6.2     | PF11195c  | 28         |
the timing of maximal expression since the loess smoothing provides and average mRNA abundance values over a time interval, correcting possible minor fluctuations in the raw value profiles. Each expression profile was subsequently normalized by its peak value. It is assumed that for each metabolic pathway there is a stoichiometric relationship between its individual enzymes and therefore the normalized values are more meaningful for functional evaluation. All enzymes discussed in this essay with their EC numbers and gene ID’s are shown in Table 2. Amplification of transcription was calculated by dividing the maximum value by the minimum value of the profile of relative mRNA abundance. A fair agreement between the time-dependent transcription data of the DeRisi transcriptome and Winzeler’s data has been observed (data not shown).

Results and Discussion
At the onset of the present analysis, it should be underscored that time-dependent transcription does not always overlaps translation. Hence, transcript levels cannot be directly extrapolated to levels of their translated product. Moreover, transient transcription does not divulge on the stability of the translated products. Indeed, a recent analysis has shown for several genes that while the transcript peaks at the trophozoite stage and declines thereafter, the translated protein continues to accumulate [23]. Significant discrepancies between mRNA and protein abundance in \textit{P. falciparum} were also reported by LeRoche et al. [24]. This was shown to be due to a delay between the maximum detection of an mRNA transcript and that of its cognate protein. Surely, a protein cannot be produced if its cognate gene is not transcribed. Therefore, the present analysis can at best set a time for possible translation but not for its actual occurrence. Thus, while transcript levels are informative for the concerted action of metabolically related enzymes, post-transcriptional mechanisms for controlling protein levels and protein stability must also be considered.

In this analysis, the transcription of genes coding for enzymes that constitute the PPP will be discussed first followed by those that are involved in the synthesis of NAD(P)\(^+\) and of thiamine pyrophosphate.

\textbf{The pentose phosphate pathway}

The pathway is shown in Figure 1 and the time-dependent transcription of the different genes is depicted in Figure 3. Whereas G6PD (EC: 1.1.1.49) and hence its conjoint 6-phosphogluconolactonase (EC: 3.1.1.31) are transcribed at high levels during the early stages of parasite development, the transcription of 6-phosphogluconate dehydrogenase (EC: 1.1.1.44) seems to be biphasic (first peak at 9 hours post invasion (HPI) while the major peak is observed at 26 HPI). The two other enzymes that need to be present for full synthesis of PRPP are ribose phosphate isomerase (EC: 5.3.1.6) and ribose-phosphate diphosphokinase (EC: 2.7.6.1). The first has a small peak at 12 HPI and a major one at 21 HPI. The parasite contains 2 genes that code for ribose-phosphate diphosphokinase (PF13_0157 and PF13_0143) – dark green filled circles. Glucose-6-phosphate dehydrogenase and 6-phosphogluconolactonase were grouped together because they constitute a chimerical protein.

![Figure 3](image-url)

\textbf{Time dependent transcription of genes coding for enzymes involved in the pentose phosphate pathway.}
Glucose-6-phosphate dehydrogenase/6-phosphogluconolactonase – black filled circles; 6-phosphogluconate dehydrogenase – red filled circles; Ribose phosphate isomerase – blue filled circles; Ribulose 5-phosphate epimerase – green filled circles. Transketolase – purple filled circles; Ribose phosphate diphosphokinase (PF13_0157) – gold filled circles and (PF13_0143) – dark green filled circles. Glucose-6-phosphate dehydrogenase and 6-phosphogluconolactonase were grouped together because they constitute a chimerical protein.
of the oxidative arm, lags considerably behind (see below). This is a crucial paradox that waits to be resolved.

The situation of the non-oxidative arm genes is different. The gene that codes for ribose phosphate isomerase (EC: 5.1.3.1) peaks at 21 HPI and this seems to restrict the expression of the non-oxidative arm, since transketolase (EC: 2.2.1.1) is transcribed maximally immediately following invasion. Most importantly, the gene that codes for transaldolase (EC: 2.2.1.2) could not be found in the genome of *P. falciparum* or in any other Plasmodium species sequenced so far, or in any other Apicomplexans for that matter) thus precluding the completion of the analysis of the non-oxidative arm transcription. As mentioned above, biochemical evidence indicates that this arm is active in the parasite. If it is indeed fully activated when ribose phosphate isomerase is transcribed (and supported by the transcription of the genes that code for ribose-phosphate diphosphokinase that peak at 21 HPI), it would match the transcription of the deoxyribo nucleotide synthesis-related genes that starts at 18 HPI and peaks at 30 HPI [2] as well as those related to NADP+ synthesis. When the synthesis of ribonucleotides and deoxyribonucleotides ebbs off towards the end of the intraerythrocytic life cycle of the parasite, the PPP probably functions according to mode 3 (Figure 2) providing both NADPH and ATP. A feature that emerges from this analysis is that the transcription of the genes that code for enzymes acting in the non-oxidative arm are coordinated as shown for other clusters of genes whose products are functionally related [1-3]. However, it remains to be seen if the cognate enzymes of these transcripts are similarly coordinated since significant discrepancies between mRNA and protein abundance has been recently reported [24].

**NAD(P) biosynthesis**

The pathway is shown in Figure 4 and the time-dependent transcription of the different genes is depicted in Figure 5. Nicotine adenine dinucleotide (NAD+) and NAD phosphate (NADP+) play key roles in glycolysis and PPP as well as many other enzymatic reactions (see Tables 3 and 1, respectively). NAD synthesis starts by converting nicotinic acid to nicotinate D-ribonucleotide by nicotinate phosphoribosyltransferase (NAPRT; EC: 2.4.2.11). Nicotinate D-ribonucleotide is then adenylated to deamino-NAD+ in a reaction catalyzed by nicotinate-nucleotide adenyltransferase (EC: 2.7.7.18) then this intermediate is amided to NAD+ by NAD synthetase (EC: 6.3.5.1). Nicotinamide can be used for NAD synthesis either by being deamidated to nicotinic acid by nicotinamidase (EC: 3.5.1.19) or by being converted to nicotinamide mononucleotide by nicotinamide phosphoribosyltransferase (NPRT; EC: 2.4.2.12) and then to NAD by NAD pyrophosphorylase (EC: 2.7.7.1). Genes coding for the two latter enzymes could not be found in the genome of

**Figure 4**

**Nicotine nucleotide metabolism.** The no-entry symbol indicates that the gene coding for this enzyme could not be found in the genome of *P. falciparum*, but biochemical evidence suggests that the enzyme activity must be present.
P. falciparum, although a measurable activity of NPRT has been detected [26]. These enzymes are present in normal erythrocytes and at physiological conditions the production of NAD⁺ from nicotinamide seems to be more important than that of NADP⁺ [27]. Zerez et al. [26] demonstrated 15-fold increase in the levels of NAD⁺ (NAD⁺ + NADH) in P. falciparum-infected erythrocytes, as well as 3-fold increase in NAPRT activity. These results indicate that the parasite is capable of NAD synthesis although neither the activity of nicotinate-nucleotide adenyltransferase or of NAD synthetase were increased in infected cells compared to uninfected erythrocytes. This observation suggests that these enzymes must be active in the parasite since the digestion of host cell cytosol during parasite development should have reduced their activities. Abundant nicotinamidase activity was also detected in infected cells implying that the parasite can synthesize NAD⁺ from both nicotinic acid and nicotinamide (both present in RPMI-1640 medium used for parasite cultivation). The concentrations of NADP⁺ in infected cells are 10-fold lower than those of NAD⁺. A gene coding for NAD⁺ kinase could not be found in the genome of P. falciparum or in any other Plasmodium species or in other Apicomplexans, but could be detected in Giardia lamblia. No information about the action of NAD kinase in the parasite could be found.

Table 3: NAD⁺-utilizing enzymes. Enzymes are arranged by their sequential functional order. They are given by their name, their EC numbers, the gene identification (PfID) in the Plasmodium genome database (PlasmoDB), the time (in hours post invasion (HPI)) in the parasite’s developmental cycle when they are maximally transcribed obtained from the IDC database, the metabolic function of the enzyme.

| Enzyme                              | EC number | PfID     | Peak (HPI) | Metabolic function                             |
|-------------------------------------|-----------|----------|------------|------------------------------------------------|
| Pyrroline carboxylate reductase     | 1.5.1.2   | MAL13P1.284 | 18         | Methionine polyamine metabolism               |
| Ferrodoxin reductase-like protein   | 1.7.1.4   | PF07_0085 | 21         | Nitrogen metabolism                           |
| Glutamate dehydrogenase            | 1.4.1.2   | PF08_0132 | 20         | Glutamine metabolism                          |
| Aminomethyltransferase             | 2.1.2.10  | PF13_0345 | 22         | Folate biosynthesis                           |
| L-lactate dehydrogenase            | 1.1.1.27  | PF13_0141 | 22         | Glycolysis                                    |
| Enoyl-acyl carrier reductase       | 1.3.1.9   | MAL6P.1.275 | 30         | Fatty acid synthesis                          |
| 2-oxoglutarate dehydrogenase el component | 1.2.4.2 | PF08_0045 | 30         | TCA cycle                                    |
| Lipoamide dehydrogenase, putative  | 1.8.1.4   | PF08_0066 | 28         | TCA cycle                                    |
| Pyruvate dehydrogenase EI component, ?-subunit | 1.2.4.1 | PF11_0256 | 28         | Fatty acid synthesis                          |
| NADH-cytochrome b5 reductase       | 1.6.2.2   | PF13_0353 | 32         | Electron transport                            |
| Malate dehydrogenase, putative     | 1.1.1.37  | MAL6P.1.242 | 34         | Pyruvate metabolism                           |
| Glycerol-3-phosphate dehydrogenase | 1.1.1.8   | PF11_0157 PFO7080w | 37 19 | Glycolysis; Glycerol metabolism               |
| GDP-mannose 4.6-dehydratase         | 1.1.1.187 | PF08_0077 | 39         | Mannose and fructose metabolism               |
| Inosine-5’-monophosphate dehydrogenase | 1.1.1.205 | PF11020c | 12         | Purine metabolism                             |
| 3-methyl-2-oxobutanoate dehydrogenase (lipoamide) | 1.2.4.4 | PFO2225w | 32         | Leucine, isoleucine and valine degradation    |
| Nitrate reductase                  | 1.7.1.1   | chr13.gim_739 | 32         | Nitrogen metabolism                           |

Figure 5
Time dependent transcription of genes coding for enzymes involved in the biosynthesis of NAD(P)+.
Nicotinamidase – purple filled circles; Nicotinate phosphoribosyl transferase – green filled circles; Nicotinate-nucleotide adenyltransferase – red filled circles; NAD⁺ synthetase – black filled circles; NAD(P) transhydrogenase – blue filled circles.
Inspection of the time-dependent transcription of genes coding enzymes that are involved in NAD(P)⁺ biosynthesis reveal an unusual pattern. Transcriptional profiles of at least three transcripts show two peaks, namely those of nicotinamidase, of nicotinate-nucleotide adenylyltransferase and of NAD(P)⁺ transhydrogenase, as compared to most other transcripts in the parasite transcriptome that are monophasic. The reason for this pattern is unclear as biochemical data are unavailable for any physiological interpretation, but it may suggest that the the enzymes are not stable. Assuming that the first smaller peak of nicotinate-nucleotide adenylyltransferase (20 HPI) is sufficient for adequate expression of enzymatic activity, the biosynthesis of NAD(P)⁺ should peak when NAD⁺ synthetase is at its peak, i.e., at 28 HPI. Thus, by 28 HPI the transcripts of all enzymes necessary for NAD⁺ synthesis are fully deployed and somewhat later, synthesis itself is probably fully deployed. This time pattern means that important activities, such as glycolysis (the transcription of genes coding for glycolytic enzymes starts to peak at 9 HPI and starts to decrease at 24 HPI) [2] At earlier stages glycolysis and PPP activity probably depend on the pool of NAD(P)⁺ that were present in the invading merozoite. For the full activation of glycolysis at the trophozoite stage [28], the pool of NAD(P)⁺ has to be significantly amplified. As can be seen in Table 3, several genes coding for enzymes requiring NAD(H) are transcribed earlier than the complete transcription of genes related to NAD⁺ synthesis. Such an outstanding exception is that of inosine-5'-monophosphate dehydrogenase, an essential enzyme in the purine metabolic pathway: it is transcribed too early to allow its translated product to be functionally useful. The functional meaning of the second peaks of nicotinamidase and of nicotinate-nucleotide adenylyltransferase is enigmatic since the transcription of all other enzyme-coding genes declines to a minimum when they peak. For being meaningful physiologically, the stability of all other enzymes must be sustained with time. Indeed, it has been recently shown that the levels of some proteins such as methionine adenosyltransferase, ornithine aminotransferase, lactate dehydrogenase, glyceraldehyde 3-phosphate dehydrogenase and enolase, are not only increased following transcription, but further increase after their transcript levels decline [23]. Finally, NAD⁺ kinase is essential for the production of NADP⁺. Its absence from the genome is indeed very perplexing because biochemical evidence indicate that the parasite is able to synthesize NADP⁺ [19] and the presence of many enzymes that need it as a cofactor, implicate that its synthesis is essential for parasite growth. As long as the gene (or some surrogate mechanism) is not identified, nothing can be said about the coordination of NADP⁺ biosynthesis and the expression of enzymes that utilize it (Table 1).

Transhydrogenase operates at an important interface between NAD(H) and NADP(H) and between the mitochondrial proton electrochemical gradient ?? [29]. Under regular physiological conditions, the enzyme is a consumer of ??:

\[ \text{NADH} + \text{NADP}⁺ + H_\text{out}^+ \rightarrow \text{NAD}⁺ + \text{NADPH} + H_\text{in}^+ \]

The energy of the gradient can drive the \([\text{NADPH}]/[\text{NAD}⁺]/[\text{NADP}⁺]/[\text{NADH}]\) ratio to values >400. Transhydrogenation can also function in the reverse direction from NADP to NAD⁺. This is accompanied by outward proton translocation and formation of ?? In this mode, the enzyme utilizes substrate binding energy for proton pumping. Therefore, in terms of energy transduction, the transhydrogenase works in principle like the ATP synthase complex of mitochondria, the proton ATPase. Given the fact that the parasite genome does not have the full complement of genes coding for the mitochondrial proton ATPase [30], it is tempting to suggest that the transhydrogenase could fulfill such role. The transcription of the gene coding for transhydrogenase shows two very distinct peaks at 20 and 30 HPI, with no detectable transcription between them. It may well be that the second peak is adjusted to the time of elongation and division of the single mitochondrion [31].

**Thiamine biosynthesis**

The essential product of this pathway, thiamine diphosphate, is a cofactor of many enzymes (Table 4). The pathway is shown in Figure 6 and the time-dependent transcription of the different genes is depicted in Figure 7. Thiamine (vitamin B₁) is the precursor of the coenzyme thiamine pyrophosphate that is involved in the action of many decarboxylating enzymes and relevant to the present analysis, in the function of transketolase. P. berghei-infected erythrocytes contain higher levels of thiamine than their uninfected counterparts [32] and thiamine deficiency retards the propagation of this parasite in vivo [33]. The incidence of thiamine deficiency in adults admitted to hospital with malaria in Thailand has been examined [34] and it was observed that in hospitalized thiamine deficiency commonly complicates acute falciparum malaria, particularly in severe infections, and could contribute to dysfunction of the central nervous system. Thiamine could be obtained by the parasite from the extracellular space (like in animal cells) and pyrophosphorylated by thiamine diphosphokinase (EC: 2.7.6.2). However the presence of genes coding for enzymes that participate in the eukaryote biosynthetic pathway of thiamine phosphate, suggest that the parasite is able to synthesize its own precursor. Nevertheless, the absence of a gene coding for thiamine phosphate kinase (EC: 2.7.4.16) must be resolved and direct biochemical demonstration of activity must be performed before a firm
**Biosynthesis of thiamine diphosphate.** The no entry symbol indicates that the gene coding for this enzyme could not be found in the genome of *P. falciparum*. No biochemical evidence exists to confirm or refute enzyme activity. It has been added to the scheme because genes coding for enzymes preceding it in the pathway are present in the genome.

**Table 4: Thiamine diphosphate utilizing enzymes.** Enzymes are arranged by their sequential functional order. They are given by their name, their EC numbers, the gene identification (PfID) in the *Plasmodium* genome database (PlasmoDB), the time (in hours post invasion (HPI)) in the parasite’s developmental cycle when they are maximally transcribed obtained from the IDC database, the metabolic function of the enzyme.

| Enzyme                               | EC number | PfID          | HPI | Metabolic function                                      |
|--------------------------------------|-----------|---------------|-----|---------------------------------------------------------|
| Pyruvate dehydrogenase E1            | 1.2.4.1   | PF11_0256 (a) | 28  | Apicoplast fatty acid synthesis                         |
|                                      |           | PF14_0441 (b) |     |                                                         |
| Transketolase                        | 2.2.1.1   | MAL6P1.110    | 17  | Pentose phosphate pathway                               |
| Oxalyl-CoA decarboxylase             | 4.1.18    | MAL6P1.231    | 26  | Glyoxylate and dicarboxylate metabolism                 |
|                                      |           | PFF0945c      | NA  |                                                         |
| L-deoxy-D-xylulose-5-phosphate synthase | 2.2.1.7  | PF13_0207     | 21  | Isoprenoid biosynthesis                                  |
| 3-methyl-2-oxobutanoate dehydrogenase | 1.2.4.4  | PFE0225w      | 32  | Leucine, isoleucine and valine degradation              |
| Oxoglutarate dehydrogenase           | 1.2.4.2   | PF08_0045     | 32  | Mitochondrial TCA cycle                                 |

**Involved in enzymatic activity of:**
- Pyruvate decarboxylase
- Pyruvate dehydrogenase
- α-ketoglutarate dehydrogenase
- Transketolase

**From extracellular medium**

**Glycolysis**

- D-Glyceraldehyde-3P → Pyruvate
- 5-(2-hydroxyethyl)-4-methylthiazole
- ATP → Hydroxymethylthiazole kinase
- ADP

**Thiamine-phosphate pyrophosphorylase**

- PPI → Thiamine phosphate
- ATP

**Thiamine diphosphokinase**

- ATP → ADP

**Thiamine triphosphokinase**

- ATP → ADP

**Purine metabolism**

- 1-(5'-phosphoribosyl)-5-aminoimidazole
- Hydroxymethylpyrimidine kinase
- ATP → ADP
- 4-amino-5-hydroxymethyl-2-methylpyrimidine
- Phosphomethylpyrimidine kinase
- ATP → ADP
- 4-amino-2-methyl-5-phosphomethylpyrimidine
- 2-methyl-4-amino-5-hydroxymethylpyrimidine-2P

**Figure 6**
statement can be made on this metabolic pathway. It is not unlikely that thiamine phosphate kinase is not needed, as is the situation in yeast [35]. There it is suggested that thiamine phosphate is hydrolyzed to thiamine by a non-specific phosphatase and thiamine is then converted to thiamine pyrophosphate by thiamine diphosphokinase.

The transcription of all genes coding for enzymes involved in thiamine pyrophosphate seems to be coordinated, single phased and peaking between 20 and 30 HPI. If thiamine is obtained from the host and thiamine pyrophosphate is synthesized by the single step mediated by thiamine diphosphokinase, the peak transcription of this gene at 28 HPI lags by several hours after that of transketolase (17 HPI), but since transketolase is not the expression time-setter of PPP, this lag does not seem to limit the full activity of PPP. However, if most of the thiamine is generated endogenously by the parasite, the supply of this precursor will peak only at 33 HPI, thus limiting full PPP activity. It is not unlikely that both processes occur in tandem or that at advanced stage of parasite development, the need for thiamine cannot be met any more by exogenous supply and the endogenous synthesis joins the game.

Conclusion
The analysis of time-dependence transcription of parasite genes concluded that the parasite has evolved a highly specialized mode of transcriptional regulation that produces a continuous cascade of gene expression, beginning with genes corresponding to general cellular processes, such as protein synthesis, and ending with Plasmodium-specific functionalities, such as genes involved in erythrocyte invasion [2]. However, a meticulous analysis shows marked and important deviations from this prototype that reveal a lack of coordinated transcription of genes coding for enzymes of the same metabolic pathway and between pathways. There are three most straightforward explanations for these apparent discrepancies. First, there are additional enzymes facilitating the “missing” activities and their identity was not revealed by the present annotations due to their diverse amino acid sequence. Second, the misaligned transcriptional regulation reflect an intricate interplay of the biosynthetic pathways where delayed production of metabolites in one pathway functions as a rate limiting factor for other pathways, which is otherwise fully deployed. Last but not least, post-transcriptional regulation may also play a role. All theories create an intriguing possibility for further studies. Clearly this effort will be enhanced by substantial progress in proteomics and most importantly, direct biochemical demonstrations of activities of individual enzymes and entire pathways.

Authors’ contributions
Each author contributed equally to this investigation.

Acknowledgements
We thank Professor I. Ohad for critical reading of the manuscript.

References
1. Ben Mamoun C, Gluzman IY, Hott C, MacMillan SK, Amarakone AS, Anderson DL, et al: Co-ordinated programme of gene expression during asexual intraerythrocytic development of the human malaria parasite Plasmodium falciparum revealed by microarray analysis. Mol Microbiol 2001, 39:26-36.
2. Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, DeRisi JL: The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol 2003, 1:E5.
3. Le Roch KG, Zhou Y, Blair PL, Grainger M, Moch JK, Haynes JD, De La Vega P, Holder AA, Batalov S, Carucci Dj, Winzeler EA: Discovery of gene function by expression profiling of the malaria parasite life cycle. Science 2003, 301:1503-1508.
4. Bozdech Z, Ginsburg H: Antioxidant defense in Plasmodium falciparum: data mining of the transcriptome. Malar J 2004, 3:23.
5. Roth EF, Raventos-Suarez C, Perkins M, Nagel RL: Glutathione stability and oxidative stress in P. falciparum infection in vitro: responses of normal and G6PD deficient cells. Biochem Biophys Res Commun 1982, 109:355-362.
6. Atamna H, Pescarmona G, Ginsburg H, Hexose-monophosphate shunt activity in intact Plasmodium falciparum infected erythrocytes and in free parasites. Mol Biochem Parasitol 1994, 67:79-89.
Glucose-6-phosphate dehydrogenase (G6PD) is a key enzyme in the pentose phosphate pathway, which is essential for nucleic acid synthesis in rapidly dividing cells such as erythrocytes infected with Plasmodium falciparum. G6PD deficiency, a common genetic trait, affects over 400 million people worldwide and can increase susceptibility to severe malaria. This review focuses on the expression and characterization of G6PD in Plasmodium falciparum-infected human erythrocytes, highlighting its role in malaria parasite biology and the potential impact of G6PD deficiency on malaria pathogenesis.

1. Cappadoro M, Giribaldi G, Obrien E, Turrini F, Mannu F, Ulliers D, Simula G, Luzzatto L, Arese P: Expression and characterization of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood 1998, 92:2527-2534.

2. Roth E, Ruprecht R, Schulman S, Vanderberg J, Olson J: Cloning of the glucose-6-phosphate dehydrogenase gene from Plasmodium falciparum. Mol Biochem Parasitol 1984, 15:313-326.

3. Sodeinde O, Clarke JL, Mason PJ: Expression of glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase – A novel bifunctional enzyme in malaria parasites. Eur J Biochem 2001, 268:2013-2019.

4. Theakston R, Ali S, Moore G: Electron microscope autoradiographic studies on the effect of chloroquine on the uptake of tritiated nucleosides and methionine by Plasmodium berghei, Ann Trop Med Parasitol 1972, 66:295-302.

5. Sherman JW: Biochemistry of plasmodium (malarial parasites). Microbiol Rev 1979, 43:453-495.

6. Kanzok SM, Schirmer RH, Turbachova I, Islof R, Becker K: The thio-redox system of the malaria parasite Plasmodium falciparum – Glutathione reduction revisited. J Biol Chem 2000, 275:40180-40186.

7. Becker K, Rahils S, Nickel C, Schirmer RH: Glutathione – functions and metabolism in the malaria parasite Plasmodium falciparum. Biol Chem 2003, 384:551-566.

8. Bodoche Z, Zhu J, Joachimiak MP, Cohen FE, Pulliam B, DeRisi JL: Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a long-oligonucleotide microarray. Genome Biol 2003, 4:R9.

9. Nirmalan N, Sims PF, Hyde JE: Quantitative proteomics of the human malaria parasite Plasmodium falciparum and its application to studies of development and inhibition. Mol Microbiol 2004, 52:1187-1199.

10. Le Roch KG, Johnson JR, Flores L, Zhou Y, Santrosyan A, Grainger M, Yan SF, Williamson KC, Holder AA, Carucci DJ, Yates JR 3rd, Winzeler EA: Global analysis of transcript and protein levels across the Plasmodium falciparum life cycle. Genome Res 2004, 14:2308-2318.

11. Scott H, Gero AM, O’Sullivan WJ: In vitro inhibition of Plasmodium falciparum by pyrazofurin, an inhibitor of pyrimidine biosynthesis de novo. Mol Biochem Parasitol 1986, 18:3-15.

12. Zerec C, Roth E, Schulman S, Tanaka K: Increased nicotinamide adenine dinucleotide content and synthesis in Plasmodium falciparum- infected human erythrocytes. Blood 1990, 75:1705-1710.